11/13
09:01 am
obio
Orchestra BioMed (NASDAQ:OBIO) had its "buy" rating reaffirmed by analysts at Chardan Capital. They now have a $20.00 price target on the stock.
Medium
Report
Orchestra BioMed (NASDAQ:OBIO) had its "buy" rating reaffirmed by analysts at Chardan Capital. They now have a $20.00 price target on the stock.
11/13
08:53 am
obio
Rating for OBIO
Medium
Report
Rating for OBIO
11/12
10:57 am
obio
Rating for OBIO
Low
Report
Rating for OBIO
11/12
10:57 am
obio
Rating for OBIO
Low
Report
Rating for OBIO